# FDA Said Yes. MHRA Said Yes. EMA Said No.

- slug: fda-said-yes-mhra-said-yes-ema-said-no
- date: 2026-04-24
- category: Biotech & Life Sciences

Three regulators examined the same cancer drug data. One said the benefit was clear. Two said it was not enough. The reason a 60% patient crossover rate confounded the survival analysis is now reshaping how companies think about building radiopharma infrastructure in Europe.

---